Search - tctmd.com

Displaying 181 - 200 of 952

Sort: Relevancy | Date

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Presenter: John A. Bittl, Robert A. Harrington, George D. Dangas

October 12, 2015

Presentation TCT 2015

Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial?

Presenter: John A. Bittl, Robert A. Harrington, Mahesh Madhavan

October 12, 2015

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Presenter: John A. Bittl, Robert A. Harrington, Jorge F. Saucedo

October 12, 2015

Presentation TCT 2015

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Presenter: John A. Bittl, Robert A. Harrington, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2015

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Roxana Mehran

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

Debate: The Case for Short-term DAPT in Most Patients!

Presenter: Regina Deible, Gennaro Giustino

October 11, 2015

Presentation TCT 2015

Debate: The Case for Long-term DAPT After Stenting In Most Patients!

Presenter: Regina Deible, Daniel I. Simon

October 11, 2015

Presentation TCT 2015

Introduction: Why Is This Issue Important? Ischemia vs Bleeding

Presenter: Regina Deible, Roxana Mehran

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Presenter: C. Michael Gibson, Marco Valgimigli, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

L.A. McKeown

October 08, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Yael L. Maxwell

October 02, 2015

Advertisement

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial?

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

Debate: The Case for Short-term DAPT in Most Patients!

Debate: The Case for Long-term DAPT After Stenting In Most Patients!

Introduction: Why Is This Issue Important? Ischemia vs Bleeding

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content